TVGN 601
Alternative Names: CD8+ T cell therapy - Tevogen Bio; CTL therapy - Tevogen Bio; Multiple sclerosis therapy - Tevogen Bio; TVGN-601Latest Information Update: 18 Nov 2022
At a glance
- Originator Tevogen Bio
- Class T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Multiple sclerosis
Most Recent Events
- 18 Nov 2022 Preclinical trials in Multiple sclerosis in USA (Parenteral) (Tevogen pipeline, November 2022)